Evusheld injection, a new COVID treatment that people can take before becoming symptomatic, in Chicago on Friday, Feb. 4, 2022.Chris Sweda | Tribune News Service | Getty ImagesThe omicron subvariants that have become dominant in recent months present a serious threat to the effectiveness of the new boosters, render antibody treatments ineffective and could cause a surge of breakthrough infections, according to a new study.The BQ.1, BQ.1.1, XBB and XBB.1 omicron subvariants are the most immune evasive variants of Covid-19 to date, according to scientists affiliated with Columbia University and the University of Michigan. These variants, taken together, are currently causing 72% of new infections in the U.S., according to data from the Centers for Disease Control and Prevention.The scientists, in a study published online Tuesday in the peer-reviewed journal Cell, found that …
